Investigation of epigenetic abnormalities involved in lung cancer progression.
Project/Area Number |
20590324
|
Research Category |
Grant-in-Aid for Scientific Research (C)
|
Allocation Type | Single-year Grants |
Section | 一般 |
Research Field |
Pathological medical chemistry
|
Research Institution | Aichi Cancer Center Research Institute |
Principal Investigator |
OSADA Hirotaka Aichi Cancer Center Research Institute, 分子腫瘍学部, 室長 (30204176)
|
Project Period (FY) |
2008 – 2010
|
Project Status |
Completed (Fiscal Year 2010)
|
Budget Amount *help |
¥4,550,000 (Direct Cost: ¥3,500,000、Indirect Cost: ¥1,050,000)
Fiscal Year 2010: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2009: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2008: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
|
Keywords | 分子腫瘍学 / 癌 / 肺癌 / エピジェネティック / マイクロRNA / 転移 / ASH1 |
Research Abstract |
Lung cancers with neuroendocrine features are usually highly metastatic and aggressive. We investigated the relationship between ASH1 signaling and epigenetic abnormalities in lung cancers, because neuroendocrine features are induced by ASH1. Our findings revealed a novel tumor suppressor candidate gene, which is suppressed by ASH1 signaling and epigenetic abnormalities. We also found ASH1-upregulated miRNA and characterized the epigenetic status of its promoter region. Finally, a tetracycline-inducible ASH1 expression system was established.
|
Report
(4 results)
Research Products
(34 results)